Viracta Therapeutics (VIRX) Competitors $0.02 0.00 (-4.32%) As of 03:47 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIRX vs. QLGN, ONCO, JAGX, VRAX, PTN, AWH, APVO, PCSA, ALZN, and CDTShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Qualigen Therapeutics (QLGN), Onconetix (ONCO), Jaguar Animal Health (JAGX), Virax Biolabs Group (VRAX), Palatin Technologies (PTN), Aspira Women's Health (AWH), Aptevo Therapeutics (APVO), Heatwurx (PCSA), Alzamend Neuro (ALZN), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Its Competitors Qualigen Therapeutics Onconetix Jaguar Animal Health Virax Biolabs Group Palatin Technologies Aspira Women's Health Aptevo Therapeutics Heatwurx Alzamend Neuro Conduit Pharmaceuticals Qualigen Therapeutics (NASDAQ:QLGN) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation. Does the media favor QLGN or VIRX? In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Viracta Therapeutics'average media sentiment score. Company Overall Sentiment Qualigen Therapeutics Neutral Viracta Therapeutics Neutral Which has more risk and volatility, QLGN or VIRX? Qualigen Therapeutics has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Do analysts recommend QLGN or VIRX? Viracta Therapeutics has a consensus target price of $1.75, suggesting a potential upside of 11,190.32%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viracta Therapeutics is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Viracta Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders have more ownership in QLGN or VIRX? 3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Comparatively, 10.7% of Viracta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, QLGN or VIRX? Qualigen Therapeutics has higher revenue and earnings than Viracta Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQualigen Therapeutics$4.98M1.12-$6.26MN/AN/AViracta TherapeuticsN/AN/A-$51.06M-$1.10-0.01 Is QLGN or VIRX more profitable? Qualigen Therapeutics' return on equity of 0.00% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qualigen TherapeuticsN/A N/A N/A Viracta Therapeutics N/A -1,899.61%-114.21% SummaryViracta Therapeutics beats Qualigen Therapeutics on 6 of the 10 factors compared between the two stocks. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$616K$784.80M$5.53B$9.03BDividend YieldN/A4.84%5.24%4.01%P/E Ratio-0.011.0919.3119.89Price / SalesN/A230.50424.59117.07Price / CashN/A23.4426.2128.59Price / Book0.056.237.925.55Net Income-$51.06M-$27.94M$3.17B$248.49M7 Day PerformanceN/A2.21%2.18%5.37%1 Month PerformanceN/A8.98%1.25%6.63%1 Year PerformanceN/A11.57%33.90%21.20% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics2.1165 of 5 stars$0.02-4.3%$1.75+11,190.3%-96.6%$616KN/A-0.0120Gap DownQLGNQualigen TherapeuticsN/A$3.41-3.9%N/A-76.7%$2.61M$4.98M0.0050ONCOOnconetix0.2903 of 5 stars$4.77-1.2%N/A-99.1%$2.57M$2.52M0.0012Gap DownJAGXJaguar Animal Health1.8329 of 5 stars$2.52+0.8%$60.00+2,281.0%-97.1%$2.55M$11.69M0.0050VRAXVirax Biolabs Group2.837 of 5 stars$0.79+1.5%$3.00+278.9%-29.1%$2.52M$160K0.005PTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's Health0.9049 of 5 stars$0.08-12.5%$5.50+6,607.3%-92.6%$2.44M$9.18M-0.07110High Trading VolumeAPVOAptevo Therapeutics2.0754 of 5 stars$3.05-1.0%$219,040.00+7,181,539.3%-100.0%$2.33M$3.11M0.0050PCSAHeatwurx3.6214 of 5 stars$0.21+4.5%$2.00+875.6%-88.8%$2.33MN/A-0.0720Gap UpALZNAlzamend Neuro2.2367 of 5 stars$2.91+0.3%$180.00+6,085.6%-91.6%$2.32MN/A0.004Positive NewsGap UpCDTConduit Pharmaceuticals0.1429 of 5 stars$2.76-4.2%N/A-99.6%$2.30MN/A-0.013News CoverageHigh Trading Volume Related Companies and Tools Related Companies QLGN Alternatives ONCO Alternatives JAGX Alternatives VRAX Alternatives PTN Alternatives AWH Alternatives APVO Alternatives PCSA Alternatives ALZN Alternatives CDT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
